This is a Phase I open-label dose-escalation trial using Anti-CD6-blocked Ricin (Anti-CD6-bR) in the treatment of patients with cutaneous T-cell lymphoma(CTCL) Anti-CD-bR is an IgG2a murine monoclonal antibody which has veeb covalently linked to blocked ricin. Intravenous doses of Anti-CD6-bR will be given continuously for 5 days via central venous catheter. Serum pharmacokinetics will be obtained for analysis with the 1st dose administered. Serum Hm and HARA levels will be followed throughout treatment.
NIH ExPorter
NIH ExPorter